We are a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, with operations in Europe, Australia, and the U.S.
We are the global leader in the understanding of and in the development of therapeutics that modulate Lymphocyte Activation Gene-3 (“LAG-3”), a cell surface molecule which plays a vital role in regulating T cells and which was discovered by our Chief Scientific Officer and Chief Medical Officer Dr. Frederic Triebel.
Our objective is to harness and strengthen the power of patients’ immune systems through therapeutic intervention for the benefit of patients’ health. We have one pre-clinical and three clinical LAG-3 product candidates under development, including two antibodies for modulating immune responses in autoimmunity and cancer, through pharmaceutical partnerships, with Novartis and GlaxoSmithKline.
Our lead product candidate is eftilagimod alpha (LAG-3Ig or IMP321), a first-in-class antigen presenting cell (APC) activator currently being investigated in clinical trials as a treatment (in combination with chemotherapy or immune therapy) for breast cancer and melanoma.
Immutep is listed on the Australian Stock Exchange (IMM) and on the NASDAQ Global Market (IMMP) in the U.S. (ADR's).
Latest Media Releases
Latest News
Company News /
by Anna Napoli -
15 days ago
07 Jan 2019 - Immutep (ASX:IMM) has announced it will enter into a new clinical trial collaboration with CYTLIMIC.
Market Reports /
by Rachael Jones -
A month ago
28 Nov 2018 - The ASX is set to open higher this morning after US stocks rose yesterday when President Donald Trump says he'll push forward with plans to increase tariffs on $200 b…
Interviews /
by Jessica Amir -
2 months ago
15 Nov 2018 - Immutep Limited (ASX:IMM) Executive Director and CEO, Marc Voigt provides an update on the company's clinical trials, collaboration with large pharma and key mileston…
Market Reports /
by Rachael Jones -
4 months ago
24 Sep 2018 - The ASX has closed slightly lower today with Lynas Corp (ASX:LYC) and Sims metals (ASX:SGM) seeing a drop. The Healthcare index was the worst performer. Real estate w…
Company News /
by Anna Napoli -
4 months ago
24 Sep 2018 - Bio tech company Immutep (ASX:IMM) has inked a deal with Pharmaceutical giants Merck and Pfizer to collaborate on an early stage clinical trial of its treatment for c…
Interviews /
by Rachael Jones -
4 months ago
06 Sep 2018 - Immutep Limited (ASX:IMM) CEO, Marc Voigt talks about the company's FY18 results, success with its clinical trial program, collaboration partners and outlook.
Market Reports /
by Rachael Jones -
5 months ago
22 Aug 2018 - Australian shares were set to open lower today despite the S&P 500 in New York hitting an all time high yesterday and equalled its longest ever bull-market run. Immut…
Company News /
by Rachael Jones -
7 months ago
19 Jun 2018 - Biotechnology company Immutep (ASX:IMM) has reached the mid-point in patient enrolment for its ongoing AIPAC Phase IIb clinical trial evaluating eftilagimod alpha in …
Company Presentations /
by -
7 months ago
31 May 2018 - Immutep Limited (ASX:IMM) CEO, Marc Voigt, CSO & CMO, Dr Frederic Triebel and Director Clinical Development, Christian Mueller present on clinical results of the comp…
Interviews /
by Jessica Amir -
8 months ago
10 May 2018 - Immutep Limited (ASX:IMM) CEO Marc Voigt talks about the company's clinical trial program, key milestones, collaborations and potential for immunotherapy.
